Evidence map›Paper›PMID 23118926›Full record

ArticlePloS one2012

Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat.

Rahul Bohra, Wenzel Schöning, Jelena Klawitter, Nina Brunner, Volker Schmitz, Touraj Shokati, Ryan Lawrence, Maria Fernanda Arbelaez, Björn Schniedewind, Uwe Christians and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Review
  3. Unlocking the Potential of Purinergic Signaling in Transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Cyclosporin A in left ventricular remodeling after myocardial infarction.American journal of physiology. Heart and circulatory physiology · 2014
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Rahul BohraiC42 Clinical Research & Development, Department of Anesthesiology, University of Colorado Denver, Aurora, Colorado, USA.
Wenzel Schöning
Jelena Klawitter
Nina Brunner
Volker Schmitz
Touraj Shokati
Ryan Lawrence
Maria Fernanda Arbelaez
Björn Schniedewind
Uwe Christians
Jost Klawitter
University of Colorado Denver · USCharité - Universitätsmedizin Berlin · DE

Funding

PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Wendy M Kohrt · 1995 to 2026
$32.6M
In Vivo Assessment of Calcineurin Inhibitor Toxicity in ChildrenR01HD070511 · NICHD · UNIVERSITY OF COLORADO DENVER · PI CHRISTIANS, UWE, THURMAN, JOSHUA M · 2011 to 2015
$1.9M
Effects of Immunosuppressants on Cell MetabolismR01DK065094 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI CHRISTIANS, UWE · 2003 to 2006
$1.2M
NICHD NIH HHS R01 HD070511NICHD NIH HHS R01HD070511NIDDK NIH HHS P30 DK048520NIDDK NIH HHS R01 DK065094
6 · The paper itself

Abstract

Enhancement of calcineurin inhibitor nephrotoxicity by sirolimus (SRL) is limiting the clinical use of this drug combination. We compared the dose-dependent effects of the structurally related everolimus (EVL) and sirolimus (SRL) alone, and in combination with cyclosporine (CsA), on the rat kidney. Lewis rats were treated by oral gavage for 28 days using a checkerboard dosing format (0, 3.0, 6.0 and 10.0 CsA and 0, 0.5, 1.5 and 3.0 mg/kg/day SRL or EVL, n = 4/dose combination). After 28 days, oxidative stress, energy charge, kidney histologies, glomerular filtration rates, and concentrations of the immunosuppressants were measured along with (1)H-magnetic resonance spectroscopy (MRS) and gas chromatography- mass spectrometry profiles of cellular metabolites in urine. The combination of CsA with SRL led to higher urinary glucose concentrations and decreased levels of urinary Krebs cycle metabolites when compared to controls, suggesting that CsA+SRL negatively impacted proximal tubule metabolism. Unsupervised principal component analysis of MRS spectra distinguished unique urine metabolite patterns of rats treated with CsA+SRL from those treated with CsA+EVL and the controls. SRL, but not EVL blood concentrations were inversely correlated with urine Krebs cycle metabolite concentrations. Interestingly, the higher the EVL concentration, the closer urine metabolite patterns resembled those of controls, while in contrast, the combination of the highest doses of CsA+SRL showed the most significant differences in metabolite patterns. Surprisingly in this rat model, EVL and SRL in combination with CsA had different effects on kidney biochemistry, suggesting that further exploration of EVL in combination with low dose calcineurin inhibitors may be of potential benefit.

Indexed as

Administration, OralAnimalsCyclosporineDrug Therapy, CombinationEverolimusGlomerular Filtration RateImmunosuppressive AgentsIsoprostanesKidneyMaleOxidative StressPrincipal Component AnalysisRatsRats, Inbred LewRegression AnalysisSirolimusCyclosporineEverolimusImmunosuppressive AgentsIsoprostanesSirolimus

Identifiers

PMID23118926
PMCPMC3485290
OpenAlexW2029942010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.